Tumor response data
| Best overall response* | PR | SD | PR + SD | PD |
|---|---|---|---|---|
| N (%) | ||||
| All patients (n = 21) | 5 (24) | 8 (38) | 13 (62) | 8 (38) |
| MSKCC intermediate risk (n = 15) | 4 (19) | 7 (33) | 11 (52) | 4 (19) |
| MSKCC poor risk (n = 6) | 1 (5) | 1 (5) | 2 (10) | 4 (19) |
| Heng intermediate risk (n = 11) | 4 (19) | 5 (24) | 9 (43) | 2 (10) |
| Heng poor risk (n = 10) | 1 (5) | 3 (14) | 4 (19) | 6 (29) |
*Restaging scans occurred after five doses of AGS-003 and cycles 2-4 of sunitinib. NOTE: Responses were determined relative to a baseline scan conducted after nephrectomy and completion of one (1) 6-week cycle of sunitinib.
PD = progressive disease; PR = partial response; SD = stable disease.